Capsaicin (Vanilloid Pseudoalkaloid · TRPV1 Agonist · Topical Analgesic · Thermogenic)
| Compound | Capsaicin |
| Chemical class | Alkaloid (Pseudoalkaloid / Vanilloid) — Phenylpropanoid-derived |
| CAS | 404-86-4 |
| Primary source | Capsicum annuum (chilli), Capsicum frutescens (bird-eye chilli, Tabasco) |
| Key applications | TRPV1 agonist, topical analgesic (OTC approved), neuropathic pain, weight management, thermogenic |
| Claim strength | High |
| Typical form | Capsaicin 0.025–8% topical cream/patch; red pepper extract standardised to capsaicinoids; capsinoid isolates |
| Buy from Herbuno | Bird-Eye Chilli Powder → |
Name origin: From Capsicum (the genus). Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is the primary capsaicinoid — a phenylpropanoid-derived vanillyl amide unique to Capsicum species. It is structurally related to gingerol (both contain the vanillyl group) but with an amide linkage rather than a ketol/ketone and a longer chain with a unique trans-double bond. Traditional use: Chilli (Mirch in Hindi, Lal Mirch = red chilli) has been cultivated and used medicinally in the Americas for over 6,000 years — introduced to Asia and Europe by Spanish and Portuguese explorers in the 16th century, now among the world’s most widely consumed spices. Traditional medical applications span: pain relief (topical counterirritant), appetite stimulation, digestive support, and antimicrobial food preservation. Research trajectory: Capsaicin is one of the most extensively studied phytochemicals in pain research. It has FDA-approved pharmaceutical applications (Qutenza 8% patch for neuropathic pain) and OTC drug approval (0.025–0.1% creams for musculoskeletal pain). Beyond pain, human RCTs support capsaicin for thermogenic weight management (increasing metabolic rate), appetite reduction, and cardiovascular benefits. The pharmacology of TRPV1 (the capsaicin receptor) has generated an entirely new class of analgesic drug discovery. Commercial source: Bird-Eye Chilli Powder and Capsicum Powder from Herbuno. See sourcing options below.
Evidence for Capsaicin Applications
Neuropathic pain — FDA-approved pharmaceutical: Qutenza (capsaicin 8% patch, prescription only) is FDA and EMA-approved for postherpetic neuralgia (shingles pain) and painful diabetic peripheral neuropathy. Single 60-minute application produces pain relief for up to 3 months via TRPV1 desensitisation — depleting substance P from nociceptive nerve terminals. Multiple RCTs confirm efficacy. Claim strength: High (pharmaceutical approval; RCT evidence).
Topical analgesic — OTC drug (0.025–0.1%): Capsaicin 0.025–0.1% creams are FDA-approved OTC external analgesics for osteoarthritis, rheumatoid arthritis, and muscle pain (counterirritant mechanism). Multiple RCTs confirm pain reduction in osteoarthritis of the hands and knees. Initial burning/stinging on application decreases with repeated use (TRPV1 desensitisation). Claim strength: High.
Thermogenic and weight management: Human RCTs with capsaicin (2–12 mg/day) demonstrate significant increases in energy expenditure (50–200 kcal/day), reduced appetite, and reductions in abdominal fat over 8–12 weeks. Meta-analysis (Lejeune et al., Whiting et al.) confirms modest but consistent thermogenic effects. Capsinoids (non-pungent capsaicin analogues from CH-19 Sweet pepper) produce equivalent thermogenic effects without the burning sensation. Claim strength: Moderate.
Cardiovascular: Epidemiological data from populations with high chilli consumption (China, USA) suggest reduced cardiovascular mortality and ischaemic heart disease incidence. Capsaicin activates TRPV1 in the cardiovascular system, promoting endothelial NO production and vasodilation. Human supplementation studies show modest improvements in lipid profiles and endothelial function. Claim strength: Moderate.
Bird-Eye Chilli Powder →
Browse Standardised Extract Powders →
Dosage & Formulator Specification
Topical OTC analgesic: 0.025–0.1% capsaicin in cream base, applied 3–4×/day. Pharmaceutical patch (Qutenza): 8% capsaicin, single 60-minute application under physician supervision. Thermogenic supplement: capsaicin 2–12 mg/day or capsinoid equivalent (25–150 mg/day capsinoids for non-pungent thermogenic effect). Capsaicin content in chilli products varies enormously — specify in Scoville Heat Units (SHU) or by HPLC capsaicinoid content (total capsaicin + dihydrocapsaicin) on CoA. Bird-Eye Chilli from Herbuno: approximately 100,000–225,000 SHU (high capsaicin content); standard red pepper: 1,000–5,000 SHU. For standardised thermogenic or topical applications, use capsaicin-standardised oleoresin rather than crude chilli powder.
Frequently Asked Questions — Capsaicin
How does capsaicin relieve pain when it initially causes burning?
Capsaicin binds TRPV1 (transient receptor potential vanilloid-1) — the heat and pain receptor — initially activating it and causing the characteristic burning sensation. However, sustained TRPV1 activation leads to receptor desensitisation: the nociceptive nerve terminals become unresponsive (via substance P depletion and TRPV1 internalisation) and pain signals are reduced. With repeated daily application (OTC cream) or a single high-dose application (8% patch), this desensitisation produces lasting analgesia. The burning on first application is therefore not a side effect but a necessary step in the mechanism of action.
What is the Scoville scale and how does it relate to capsaicin content?
The Scoville scale (SHU, Scoville Heat Units) measures capsaicinoid concentration by organoleptic testing (now standardised to HPLC). Pure capsaicin measures 15–16 million SHU. Common peppers: bell pepper (0 SHU), jalapeño (2,500–8,000 SHU), cayenne (30,000–50,000 SHU), bird-eye chilli (100,000–225,000 SHU), habanero (100,000–350,000 SHU). For supplement formulation: 1 mg capsaicin ≈ 16 SHU per mg of pure standard; commercial preparations are expressed as mg capsaicin per gram or by HPLC total capsaicinoid content.
Can capsaicin cause gastric damage?
A common misconception is that chilli causes ulcers. Epidemiological and clinical evidence shows the opposite — populations with high chilli consumption have lower rates of peptic ulcer disease. Capsaicin at low concentrations stimulates mucus secretion and mucosal blood flow via gastric TRPV1, which is gastroprotective. At very high concentrations (acute high-dose ingestion), capsaicin can cause gastric irritation and temporary GI discomfort. Moderate habitual consumption (as in traditional cuisines) is not associated with GI damage.
What are capsinoids and are they better than capsaicin for supplements?
Capsinoids (capsiate, dihydrocapsiate, nordihydrocapsiate) are non-pungent capsaicin analogues found in the CH-19 Sweet cultivar of Capsicum annuum. They bind TRPV1 with slightly lower affinity than capsaicin but produce equivalent thermogenic effects (brown adipose tissue activation, energy expenditure increase) without the burning sensation. For thermogenic supplements where palatability and tolerability are priorities, capsinoids at 25–150 mg/day are commercially preferred over pungent capsaicin. Multiple RCTs confirm capsinoid thermogenic efficacy comparable to capsaicin.
Related compounds: Gingerol, Shogaol, Thymoquinone, Menthol
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery